CTMX
$4.45-0.33 (-6.90%)
CytomX Therapeutics, Inc.
Recent News
A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results
CytomX Therapeutics (CTMX) is back in focus after reporting early Phase 1 expansion results for its EpCAM-targeting ADC, Varsetatug masetecan, in advanced colorectal cancer, alongside fresh earnings and a sizeable equity raise. See our latest analysis for CytomX Therapeutics. The latest EpCAM ADC data and the US$250.0m follow on equity raise have arrived after a sharp run, with a very large 1 year total shareholder return and a 3 year total shareholder return of 161.76%, even though the 30...
Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 11 Most Active Small Cap Stocks to Buy. On March 18, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw Jefferies raise its price target to $16 from $8 while maintaining a Buy rating following encouraging Phase 1 data for its lead asset Varseta-M in late-line metastatic colorectal cancer. The analyst highlighted the therapy’s […]
Sector Update: Health Care Stocks Slip Late Afternoon
Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 1.6% and
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.